A Tolerability Study of ALKS 8700 in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS) EVOLVE-MS-2

Key Inclusion Criteria:

• Capable of understanding and complying with the protocol

• Has a confirmed diagnosis of RRMS

• Neurologically stable with no evidence of relapse within 30 days prior torandomization

• Agrees to use an acceptable method of contraception for the duration of the study andfor 30 days after any study drug administration, or is surgically sterile orpost-menopausal

Key Exclusion Criteria:

• Have any finding(s) that would compromise the safety of the subject, affect thesubject's ability to adhere to the protocol visit schedule or to fulfill visitrequirements, or would make the subject unsuitable for participation in the study

• Diagnosis of primary progressive, secondary progressive, or progressive relapsing MS

• History of clinically significant cardiovascular, pulmonary, GI, dermatologic,psychiatric, neurologic (other than MS), endocrine, renal, and/or other major diseasethat would preclude participation in a clinical trial

• History of GI surgery (except appendectomy that occurred more than 6 months prior toscreening

• History of clinically significant recurring or active gastrointestinal symptoms (eg,nausea, diarrhea, dyspepsia, constipation) within 3 months of screening

• Chronic use (7 days) of medical therapy to treat any GI symptoms within 1 month ofscreening Has a clinically significant medical condition or observed abnormality atscreening

• History of a myocardial infarction, including a silent myocardial infarction orunstable angina

• History of clinically significant drug or alcohol abuse within the past year prior toscreening

• Clinically significant history of suicidal ideation or suicidal behavior in the last 12 months

• Subject is pregnant or breastfeeding or plans to become pregnant or beginbreastfeeding at any point during the study and for 30 days after any study drugadministration

• Prior use of Dimethyl Fumarate (DMF) NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.